Abstract
We present a novel case of an urticaria multiforme-type drug reaction to
the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor +
ivacaftor). Equipped with this information, clinicians may be more
prepared to counsel and treat patients if they experience similar
symptoms after beginning Trikafta.